KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EBITDA (2016 - 2025)

Historic EBITDA for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $25.5 million.

  • Travere Therapeutics' EBITDA rose 14698.76% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.6 million, marking a year-over-year increase of 7460.65%. This contributed to the annual value of -$320.2 million for FY2024, which is 19120.04% down from last year.
  • Travere Therapeutics' EBITDA amounted to $25.5 million in Q3 2025, which was up 14698.76% from -$12.7 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year EBITDA high stood at $150.9 million for Q3 2023, and its period low was -$136.5 million during Q1 2024.
  • Its 5-year average for EBITDA is -$48.4 million, with a median of -$59.3 million in 2024.
  • As far as peak fluctuations go, Travere Therapeutics' EBITDA plummeted by 365366.71% in 2021, and later skyrocketed by 32108.51% in 2023.
  • Travere Therapeutics' EBITDA (Quarter) stood at -$51.6 million in 2021, then crashed by 33.76% to -$69.0 million in 2022, then decreased by 27.44% to -$88.0 million in 2023, then skyrocketed by 32.56% to -$59.3 million in 2024, then soared by 142.92% to $25.5 million in 2025.
  • Its EBITDA stands at $25.5 million for Q3 2025, versus -$12.7 million for Q2 2025 and -$42.0 million for Q1 2025.